Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Pharmacologic induction of fetal hemoglobin (HbF) expression is an effective treatment strategy for sickle cell disease (SCD) and β-thalassemia. Pomalidomide is a potent structural analog of thalidomide and member of a new class of immunomodulatory drugs. Recent reports demonstrated that pomalidomide reduced or eliminated transfusion requirements in certain hematologic malignancies and induced HbF ex vivo in CD34+ progenitor cells from healthy and SCD donors. We investigated the effects of pomalidomide on erythropoiesis and hemoglobin synthesis in a transgenic mouse model of SCD. We found that 8 weeks of treatment with pomalidomide induced modest increases of HbF with similar efficacy as hydroxyurea. However, in stark contrast to hydroxyurea's myelosuppressive effects, pomalidomide augmented erythropoiesis and preserved bone marrow function. Surprisingly, combinatory therapy with both drugs failed to mitigate hydroxyurea's myelotoxic effects and caused loss of HbF induction. These findings support further evaluation of pomalidomide as a novel therapy for SCD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340
Nagel, R. L., Bookchin, R. M., Johnson, J., Labie, D., Wajcman, H., Isaac-Sodeye, W. A., Honig, G. R., Schilirò, G., Crookston, J. H., & Matsutomo, K. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.2.670 · Cited by 196
Cited by
Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies
Manwani, D., & Frenette, P. S. (2013) · Blood · doi:10.1182/blood-2013-05-498311 · Cited by 428
“Unfortunately, combination therapy of hydroxyurea with sodium dimethylbutyrate in a clinical trial and with pomalidomide in a murine model resulted in a blunted HbF response.(30,31) Both agents are being evaluated in clinical trials individually.”
BackgroundClinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia
Musallam, K. M., Taher, A. T., Cappellini, M. D., & Sankaran, V. G. (2013) · Blood · doi:10.1182/blood-2012-10-408021 · Cited by 204
“Promising roles of thalidomide derivatives (pomalidomide and lenalidomide) for the induction of HbF also were reported in 2008 and 2011 from in vitro and animal studies.(133,134) These findings support the evaluation of such agents as a potential new therapy that may not have the cytotoxic side effects associated with…”
BackgroundReawakening fetal hemoglobin: prospects for new therapies for the β-globin disorders
Bauer, D. E., Kamran, S. C., & Orkin, S. H. (2012) · Blood · doi:10.1182/blood-2012-06-292078 · Cited by 177
Fetal haemoglobin in sickle-cell disease: from genetic epidemiology to new therapeutic strategies
Lettre, G., & Bauer, D. E. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01341-0 · Cited by 104
A molecular glue degrader of the WIZ transcription factor for fetal hemoglobin induction
Ting, P. Y., Borikar, S., Kerrigan, J. R., Thomsen, N. M., Aghania, E., Hinman, A. E., Reyes, A., Pizzato, N., Fodor, B. D., Wu, F., et al. (2024) · Science · doi:10.1126/science.adk6129 · Cited by 97
Metadata
- Authors
- Meiler, S. E., Wade, M., Kutlar, F., Yerigenahally, S. D., Xue, Y., Moutouh-de Parseval, L. A., Corral, L. G., Swerdlow, P. S., & Kutlar, A.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2011-07-28
- Volume
- 118
- Issue
- 4
- Pages
- 1109-1112
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2054016680
- Cited by
- 88
- References
- 2
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice. https://app.cochat.ai/papers/10.1182/blood-2010-11-319137
- The paper
- Meiler, S. E., Wade, M., Kutlar, F., Yerigenahally, S. D., Xue, Y., Moutouh-de Parseval, L. A., Corral, L. G., Swerdlow, P. S., & Kutlar, A. (2011). Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice. Blood. https://doi.org/10.1182/blood-2010-11-319137
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.